Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/13757
Title: Glaucarubinone combined with gemcitabine improves pancreatic cancer survival in an immunocompetent orthotopic murine model
Authors: Yeo, Dannel;Huynh, Nhi;Beutler, John A;Baldwin, Graham S;He, Hong;Nikfarjam, Mehrdad
Issue Date: Dec-2016
EDate: 2016-03-30
Citation: Journal of Investigative Surgery 2016; 29(6): 366-372
Abstract: BACKGROUND: Pancreatic cancer continues to have a poor survival rate with an urgent need for improved treatments. Glaucarubinone, a natural product first isolated from the seeds of the tree Simarouba glauca, has recently been recognized as having anti-cancer properties that may be particularly applicable to pancreatic cancer. METHODS: The effect of glaucarubinone on the growth and migration of murine pancreatic cancer cells was assessed by 3H-thymidine incorporation assay. The survival impact of glaucarubinone alone and in combination with gemcitabine chemotherapy was assessed using an immunocompetent orthotopic murine model of pancreatic cancer. RESULTS: Glaucarubinone inhibited the growth of the murine pancreatic cancer cell lines LM-P and PAN02. Treatment with either glaucarubinone or gemcitabine reduced proliferation in vitro and the combination was synergistic. The combination treatment improved survival two-fold compared to gemcitabine treatment alone (p = 0.046) in PAN02 cells. CONCLUSIONS: The synergistic inhibition by glaucarubinone and gemcitabine observed in vitro and the improved survival in vivo suggest that glaucarubinone may be a useful adjunct to current chemotherapy regimens
URI: http://ahro.austin.org.au/austinjspui/handle/1/13757
ORCID: 0000-0002-0944-8747
0000-0003-4866-276X
PubMed URL: http://www.ncbi.nlm.nih.gov/pubmed/27027695
Type: Journal Article
Subjects: Gemcitabine
Glaucarubinone
Prostatic Neoplasms
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.